Blog

Aquatic Animal Health Updates: New Treatment Options, Drug Approvals & Industry Research

New Peracetic Acid INAD Available for Aquaculture Operations

The U.S. Fish and Wildlife Service’s Aquatic Animal Drug Approval Partnership (AADAP) has announced the availability of Peracetic Acid (VIGOROX® Clear) under INAD #14-172. The authorization covers all freshwater and saltwater fish and shrimp species, including eggs.

The treatment may be used to address waterborne pathogens, including bacteria, viruses, parasites, and fungi, in recirculating aquaculture systems (RAS) and pond environments.

Facilities interested in participating must submit a facility-specific effluent table to the FDA and receive approval before using the treatment under the INAD. This provides aquaculture producers with another potential tool for managing aquatic animal health and improving on-farm biosecurity.

For additional information, contact Bonnie Johnson at bonnie_johnson@fws.gov.

Upcoming Webinar: AADAP, the National INAD Program, and New AQUI-S® E10% Approval

The U.S. Fish and Wildlife Service will host a Fish and Aquatic Conservation Webinar on December 10, 2026, at 3:00 p.m. EST, featuring Bonnie Johnson of AADAP.

The presentation will provide an overview of the Aquatic Animal Drug Approval Partnership (AADAP) Program and the National Investigational New Animal Drug (INAD) Program, including how participating facilities gain access to investigational fish drugs under FDA-authorized protocols while helping generate the data needed for future drug approvals and expanded uses.

A featured topic will be the recent FDA approval of AQUI-S® E10%, an immediate-release sedative for wild freshwater finfish. The product is intended for use during activities such as spawning, tagging, weighing, measuring, and other fisheries management procedures.

The webinar will also highlight AADAP research supporting the development of aquatic animal health products, including sedatives, immersion treatments, medicated feeds, and spawning aids.

The webinar is open to anyone interested in aquatic animal health, aquaculture, and fisheries management.

REGISTER FOR THE DECEMBER 10 WEBINAR

AADAP Participates in International Aquatic Animal Health Symposium

In September 2026, Guppy Blair, Branch Manager of the U.S. Fish and Wildlife Service’s Aquatic Animal Drug Approval Partnership (AADAP) Program, participated in the 10th International Symposium on Aquatic Animal Health in Bodø, Norway.

The international symposium is a leading forum for advancing aquatic animal health science and practice. This year’s theme, “The Science and Practice of Fish Health and Welfare—From Physiology to the Farm,” brought together experts from academia, government, and industry to discuss emerging research, technologies, and practical approaches to improving aquatic animal health and sustainability.

Blair presented “The US Fish and Wildlife Service’s Aquatic Animal Drug Approval Partnership Program: Providing New Medications to Aquaculture and Fisheries Professionals in the U.S.” as part of a session focused on current approaches to mitigating antimicrobial resistance (AMR).

The presentation highlighted the important role AADAP plays in advancing aquatic animal drug development and providing fisheries and aquaculture professionals with access to new treatment options.

Post a comment

Skip to content